Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 8/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17455197 | 0.98 | QDPR (0.96) | QDPRHTR2CSIGMAR1ESR1ESR2 | |
| Tert-Butyl Formate SCHEMBL27618488 | 0.82 | QDPR (0.67) | QDPRHTR2CSIGMAR1ESR1ESR2 | |
| SCHEMBL7744628 | 0.81 | QDPR (1.00) | QDPRHTR2CSIGMAR1ESR1ESR2 | |
| SCHEMBL31367896 | 0.81 | QDPR (1.00) | QDPRHTR2CSIGMAR1ESR1ESR2 | |
| SCHEMBL10354311 | 0.81 | QDPR (0.68) | QDPRHTR2CSIGMAR1ESR1ESR2 | |
| SCHEMBL21228136 | 0.80 | HTR2C (0.66) | QDPRHTR2CSIGMAR1ESR1ESR2 | |
| SCHEMBL29914651 | 0.80 | HTR2C (0.66) | QDPRHTR2CSIGMAR1ESR1ESR2 | |
| SCHEMBL19998281 | 0.79 | HTR2C (0.66) | QDPRHTR2CSIGMAR1NAMPT | |
| SCHEMBL532892 | 0.79 | HTR2C (0.66) | QDPRHTR2CSIGMAR1 | |
| Hydrochloric Acid SCHEMBL10354312 | 0.79 | QDPR (0.66) | QDPRHTR2CSIGMAR1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969723-B2 | 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient | HYUNDAI PHARM CO., LTD (KR) | 2018-05-15 | — | — | US | disclosed |
| US-9969723-B2 | 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient | HYUNDAI PHARM CO., LTD (KR) | 2018-05-15 | — | — | US | disclosed |
| US-20170296539-A1 | COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4--(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES | HYUNDAI PHARM CO., LTD. (KR) | 2017-10-19 | — | — | US | disclosed |
| US-20170296539-A1 | COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4--(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES | HYUNDAI PHARM CO., LTD. (KR) | 2017-10-19 | — | — | US | disclosed |
| EP-3207928-A2 | COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES | Hyundai Pharm Co., Ltd. (KR) | 2017-08-23 | — | — | EP | disclosed |
| US-20160024063-A1 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | HYUNDAI PHARM CO., LTD (KR) | 2016-01-28 | — | — | US | disclosed |
| US-20160024063-A1 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | HYUNDAI PHARM CO., LTD (KR) | 2016-01-28 | — | — | US | disclosed |
| US-5874433-A | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| US-5773469-A | Diaryl antimicrobial agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997048674-A1 | DIARYL ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5502050-A | DIHYDROXYPHENYL-SUBSTITITED PYRIDINES OR QUINONES, HYPERTENSIVE AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-5036075-A | Serotonin antagonists | RHONE-POULENC SANTE (FR) | 1991-07-30 | — | — | US | disclosed |
| US-5021420-A | Antiserotonine agents; central nervous system, gastroin-testinal and cardiovascular disorders | RHONE-POULENC SANTE (FR) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024063-A1 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | GPR119, INSR, IRS1 | QDPR 3861/4885HTR2C 2854/4885SIGMAR1 1092/4885 |
| US-20170296539-A1 | COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4--(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES | SLC5A2, SLC5A1, DPP4 | QDPR 1837/4885HTR2C 586/4885SIGMAR1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.